Indication

CTLA4 Haploinsufficiency

1 clinical trial

1 product

Clinical trial

Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

Status: Withdrawn, Estimated PCD: 2023-11-30

Product